NVS - Novartis AG
After hours:
| Previous Close | 97.78 |
| Open | 98.19 |
| Bid | 96.56 x 1800 |
| Ask | 99.11 x 800 |
| Day's Range | 97.73 - 98.83 |
| 52 Week Range | 74.09 - 105.56 |
| Volume | |
| Avg. Volume | 2,150,622 |
| Market Cap | 207.425B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 30.02 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.50 (3.58%) |
| Ex-Dividend Date | Mar 09, 2023 |
| 1y Target Est | N/A |
- Zacks
Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
- Zacks
Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
- Zacks
Time to Buy Stock in These Pharmaceutical Giants for EPS Growth
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
- Zacks
Alimera (ALIM) Completes Enrollment in Eye Disease Study
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
- Zacks
Novo Nordisk (NVO) Collaborates for Gene-Editing Therapies
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
- Zacks
Zacks.com featured highlights W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis
W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis have been highlighted in this Screen of The Week article.
- Zacks
Novo Nordisk (NVO) Announces Positive Obesity Program Data
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
- Zacks
Invest in These Dividend Growth Stocks Amid Default Fears
Dividend stocks W.W. Grainger (GWW), Graphic Packaging (GPK), PulteGroup (PHM), Walmart (WMT) and Novartis (NVS) could be solid choices for your portfolio.
- Zacks
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
- Zacks
Novartis (NVS) Up 10.8% YTD on Strong Q1, Pipeline Progress
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
- Zacks
Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
- Zacks
AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
- Simply Wall St.
Is Novartis AG's (VTX:NOVN) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Most readers would already be aware that Novartis' (VTX:NOVN) stock increased significantly by 15% over the past three...
- Zacks
Roche's (RHHBY) MS Drug Meets Goals in the Phase II Study
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.
- Zacks
Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
- Zacks
Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth
Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.
- Zacks
Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline
Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.
- Yahoo Finance
Novartis CEO criticizes US, EU efforts to curb drug company power
Novartis CEO pushes back against government attempts to direct pharma R&D
- Zacks
What Makes Novartis (NVS) a Strong Momentum Stock: Buy Now?
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
- Zacks
Top Stock Reports for Eli Lilly, Verizon Communications & United Parcel Service
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).
- Zacks
Here's Why Novartis (NVS) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- Yahoo Finance Video
Novartis ‘focusing on high-end, innovative medicines,’ CEO says
Novartis CEO Vas Narasimhan joins Yahoo Finance Live to discuss company earnings, focusing efforts on fighting cancer, consumer health, and cutting roughly 10% of the global healthcare company’s experimental drug pipeline.
- Zacks
Zacks.com featured highlights include PulteGroup, Novartis, Boyd Gaming, Cummins and W.W. Grainger
PulteGroup, Novartis, Boyd Gaming, Cummins and W.W. Grainger are part of the Zacks Screen of the Week article.
- Zacks
5 Dividend Growth Stocks to Buy for Safe Returns
PulteGroup (PHM), Novartis (NVS), Boyd Gaming (BYD), Cummins (CMI) and W.W. Grainger (GWW) could be solid choices for your portfolio.
